JPH0122267B2 - - Google Patents
Info
- Publication number
- JPH0122267B2 JPH0122267B2 JP51031184A JP3118476A JPH0122267B2 JP H0122267 B2 JPH0122267 B2 JP H0122267B2 JP 51031184 A JP51031184 A JP 51031184A JP 3118476 A JP3118476 A JP 3118476A JP H0122267 B2 JPH0122267 B2 JP H0122267B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- halogen atom
- alkyl
- methyl
- dihydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB11644/75A GB1502312A (en) | 1975-03-20 | 1975-03-20 | Quinolone derivatives |
| GB4204375 | 1975-10-14 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS51118773A JPS51118773A (en) | 1976-10-18 |
| JPH0122267B2 true JPH0122267B2 (enExample) | 1989-04-25 |
Family
ID=26248416
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP51031184A Granted JPS51118773A (en) | 1975-03-20 | 1976-03-22 | Quinolone alkane acid derivatives preparation method and pharmaceutical composite containing derivatives |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US4066651A (enExample) |
| JP (1) | JPS51118773A (enExample) |
| AU (1) | AU1147676A (enExample) |
| CS (1) | CS188273B2 (enExample) |
| DD (1) | DD124117A5 (enExample) |
| DE (1) | DE2611824A1 (enExample) |
| DK (1) | DK115376A (enExample) |
| ES (1) | ES446234A1 (enExample) |
| FI (1) | FI760729A7 (enExample) |
| FR (1) | FR2304342A1 (enExample) |
| HU (1) | HU172032B (enExample) |
| IE (1) | IE43079B1 (enExample) |
| IL (1) | IL49126A0 (enExample) |
| LU (1) | LU74594A1 (enExample) |
| NL (1) | NL7602834A (enExample) |
| NO (1) | NO760993L (enExample) |
| PT (1) | PT64921B (enExample) |
| SE (1) | SE434394B (enExample) |
| SU (1) | SU648090A3 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE47592B1 (en) * | 1977-12-29 | 1984-05-02 | Ici Ltd | Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture |
| US5225402A (en) * | 1989-02-10 | 1993-07-06 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
| EP0382185B1 (en) * | 1989-02-10 | 1994-06-15 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
| US5412104A (en) * | 1990-09-07 | 1995-05-02 | Schering Corporation | Ester and alkoxy substituted benzopyrans |
| CA2066104C (en) * | 1991-04-19 | 2003-05-27 | Hidenori Ogawa | Benzazepine derivatives as vasopressin antagonists |
| DE69207560T2 (de) * | 1991-06-07 | 1996-06-27 | Otsuka Pharma Co Ltd | Antidiabetikum |
| DE19839499A1 (de) * | 1998-08-29 | 2000-03-02 | Merck Patent Gmbh | 2-Oxo-2H-chinolinderivate |
| WO2001016133A2 (en) | 1999-08-27 | 2001-03-08 | Ligand Pharmaceuticals Incorporated | 8-substituted-6-trifluoromethyl-9-pyrido[3,2-g]quinoline compounds as androgen receptor modulators |
| CZ2002711A3 (cs) * | 1999-08-27 | 2003-11-12 | Ligand Pharmaceuticals Incorporated | Modulátory androgenních receptorů, způsoby jejich výroby a způsoby jejich použití |
| US6566372B1 (en) | 1999-08-27 | 2003-05-20 | Ligand Pharmaceuticals Incorporated | Bicyclic androgen and progesterone receptor modulator compounds and methods |
| US6593493B1 (en) | 1999-09-14 | 2003-07-15 | Ligand Pharmaceuticals, Inc. | RXR modulators with improved pharmacologic profile |
| FR2811912B1 (fr) * | 2000-07-21 | 2003-02-07 | Gattefosse Ets Sa | Procede d'enrobage de particules solides par un agent thermofusible, et particules solides ainsi enrobees |
| US7816372B2 (en) * | 2003-08-22 | 2010-10-19 | Ligand Pharmaceuticals Incorporated | 6-cycloamino-2-quinolinone derivatives as androgen receptor modulator compounds |
| GB0420722D0 (en) * | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| AR059898A1 (es) * | 2006-03-15 | 2008-05-07 | Janssen Pharmaceutica Nv | Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2 |
| TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
| TW200845978A (en) * | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
| CA2697399C (en) | 2007-09-14 | 2016-01-19 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones |
| US8722894B2 (en) * | 2007-09-14 | 2014-05-13 | Janssen Pharmaceuticals, Inc. | 1,3-disubstituted-4-phenyl-1H-pyridin-2-ones |
| MX2010002536A (es) | 2007-09-14 | 2010-08-10 | Ortho Mcneil Janssen Pharm | 4-fenil-3,4,5,6-tetrahidro-2h, 1'h-[1,4]bipiridinil-2'-onas 1',3'-disubstituidas. |
| MX2010005110A (es) * | 2007-11-14 | 2010-09-09 | Ortho Mcneil Janssen Pharm | Derivados de imidazo[1,2-a]piridina y su uso como moduladores alostericos positivos de los receptores de glutamato metabotropico 2. |
| US20110236394A1 (en) * | 2007-11-15 | 2011-09-29 | Universite Laval | Methods for the regulation of the prostaglandin f synthase (pgfs) activity of akr1b1 and uses thereof |
| BRPI0918055A2 (pt) | 2008-09-02 | 2015-12-01 | Addex Pharmaceuticals Sa | derivados de 3-azabiciclo[3,1,0]hexila como moduladores de receptores metabotrópicos de glutamato. |
| JP5656848B2 (ja) | 2008-10-16 | 2015-01-21 | ジャンセン ファーマシューティカルズ， インコーポレイテッド． | 代謝型グルタミン酸受容体モジュレーターとしてのインドールおよびベンゾモルホリンの誘導体 |
| CA2744138C (en) | 2008-11-28 | 2015-08-11 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors |
| ES2409006T3 (es) | 2009-05-12 | 2013-06-24 | Janssen Pharmaceuticals Inc. | Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de los receptores mGluR2 |
| MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| SG176021A1 (en) | 2009-05-12 | 2011-12-29 | Janssen Pharmaceuticals Inc | 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders |
| US9012448B2 (en) | 2010-11-08 | 2015-04-21 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors |
| PL2649069T3 (pl) | 2010-11-08 | 2016-01-29 | Janssen Pharmaceuticals Inc | Pochodne 1,2,4-triazolo[4,3-a]pirydyny i ich zastosowanie jako dodatnich allosterycznych modulatorów receptorów mGluR2 |
| WO2012062759A1 (en) | 2010-11-08 | 2012-05-18 | Janssen Pharmaceuticals, Inc. | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
| JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
| JO3367B1 (ar) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
| PT3096790T (pt) | 2014-01-21 | 2019-10-15 | Janssen Pharmaceutica Nv | Combinações compreendendo moduladores alostéricos positivos ou agonistas ortostéricos do recetor glutamatérgico metabotrópico do subtipo 2 e seu uso |
| EA202192105A3 (ru) | 2014-02-04 | 2022-02-28 | Янссен Фармацевтика Нв | Комбинации, содержащие положительные аллостерические модуляторы или ортостерические агонисты метаботропного глутаматергического рецептора 2 подтипа, и их применение |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3772301A (en) * | 1971-11-22 | 1973-11-13 | Warner Lambert Co | (4-substituted)4-(methylsulfinyl)methylcarbostyrils |
-
1976
- 1976-02-23 IE IE352/76A patent/IE43079B1/en unknown
- 1976-02-25 SE SE7602339A patent/SE434394B/xx not_active IP Right Cessation
- 1976-02-27 AU AU11476/76A patent/AU1147676A/en not_active Expired
- 1976-03-01 US US05/662,685 patent/US4066651A/en not_active Expired - Lifetime
- 1976-03-01 IL IL49126A patent/IL49126A0/xx unknown
- 1976-03-17 DK DK115376A patent/DK115376A/da unknown
- 1976-03-18 FI FI760729A patent/FI760729A7/fi not_active Application Discontinuation
- 1976-03-18 NL NL7602834A patent/NL7602834A/xx not_active Application Discontinuation
- 1976-03-18 DD DD191915A patent/DD124117A5/xx unknown
- 1976-03-18 LU LU74594A patent/LU74594A1/xx unknown
- 1976-03-19 FR FR7608061A patent/FR2304342A1/fr active Granted
- 1976-03-19 CS CS761804A patent/CS188273B2/cs unknown
- 1976-03-19 SU SU762337250A patent/SU648090A3/ru active
- 1976-03-19 DE DE19762611824 patent/DE2611824A1/de active Granted
- 1976-03-19 NO NO760993A patent/NO760993L/no unknown
- 1976-03-19 PT PT64921A patent/PT64921B/pt unknown
- 1976-03-19 HU HU76IE00000737A patent/HU172032B/hu unknown
- 1976-03-20 ES ES446234A patent/ES446234A1/es not_active Expired
- 1976-03-22 JP JP51031184A patent/JPS51118773A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| FR2304342A1 (fr) | 1976-10-15 |
| DK115376A (da) | 1976-09-21 |
| AU1147676A (en) | 1977-09-01 |
| FI760729A7 (enExample) | 1976-09-21 |
| NL7602834A (nl) | 1976-09-22 |
| SE7602339L (sv) | 1976-09-21 |
| CS188273B2 (en) | 1979-02-28 |
| PT64921B (en) | 1977-08-24 |
| DE2611824A1 (de) | 1976-09-30 |
| IE43079B1 (en) | 1980-12-17 |
| DD124117A5 (enExample) | 1977-02-02 |
| PT64921A (en) | 1976-04-01 |
| SE434394B (sv) | 1984-07-23 |
| NO760993L (enExample) | 1976-09-21 |
| LU74594A1 (enExample) | 1977-05-06 |
| HU172032B (hu) | 1978-05-28 |
| SU648090A3 (ru) | 1979-02-15 |
| IL49126A0 (en) | 1976-05-31 |
| US4066651A (en) | 1978-01-03 |
| ES446234A1 (es) | 1977-10-01 |
| DE2611824C2 (enExample) | 1987-06-19 |
| FR2304342B1 (enExample) | 1979-09-21 |
| IE43079L (en) | 1976-09-20 |
| JPS51118773A (en) | 1976-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH0122267B2 (enExample) | ||
| JPH0262532B2 (enExample) | ||
| US4457927A (en) | Pyrido[2,1-b]quinazolinone derivatives and the preparation and use thereof | |
| CS208153B2 (en) | Method of making the 5-/4-pyridyl/-6-/4-fluorphebyl/-2,3-dihydroimidazo 2,1-b thiazole | |
| KR100378892B1 (ko) | 류코트리엔-길항활성을갖는벤조피란유도체 | |
| JPWO1994024087A1 (ja) | リグナン系化合物の製造方法 | |
| JPH0146514B2 (enExample) | ||
| JPH02346B2 (enExample) | ||
| DD145101A5 (de) | Verfahren zur herstellung von inda yl-derivaten | |
| JPS6236382A (ja) | チエノピリドン治療薬及びその製法 | |
| US4755509A (en) | Heterocyclic aldose reductase inhibitors and methods of using them | |
| JPH0390063A (ja) | 二置換された（キノリン―２―イル―メトキシ）フエニル酢酸誘導体 | |
| JPH05112484A (ja) | α，α−ジアルキルベンジル誘導体、その製造方法、およびそれを含有する５−リポキシゲナーゼ阻害作用を有する調剤学的組成物 | |
| JPS6228793B2 (enExample) | ||
| US4128666A (en) | 4 AND 5-Halo substituted 2-indanamine compounds | |
| US4845100A (en) | Carbostyril derivatives and salts thereof, processes for preparing the same and cardiotonic composition containing the same | |
| US4138490A (en) | Analgesic compositions containing 1,2-dihydro-2-oxoquinol-4-ylpropionic acid derivatives | |
| CA2433623A1 (en) | Pyridine derivatives useful as cyclooxygenase inhibitor | |
| JPH01228963A (ja) | ５‐アミノ‐４，６‐ジハロゲノ‐ピリジン類の製法 | |
| JPH04244063A (ja) | フエニルスルホンアミド置換されたピリジンアルケン−および−アミノオキシアルカンカルボン酸誘導体 | |
| JPH06157543A (ja) | 新規のチエノチアジン誘導体、その製造方法並びにその使用方法 | |
| JPS6333378A (ja) | ピリド〔１，８〕ナフチリジノン、その製造方法及びそれらの化合物を含有する製剤 | |
| JPS64951B2 (enExample) | ||
| JPS6216469A (ja) | ２−置換シクロヘプトイミダゾ−ル誘導体、抗潰瘍剤及びその製造方法 | |
| Elderfield et al. | Synthesis of 2-Phenyl-4-chloroquinolines1 |